Description of the medicine: Solution of polyvinylpyrrolidone 15% for injection (Solutio Polyvinylpyrrolidoni 15% pro injectionibus)

SOLUTION OF POLYVINYLPYRROLIDONE 15% FOR INJECTION (Solutio Polyvinylpyrrolidoni 15% pro injectionibus).

Transparent yellow liquid with a faint specific odor of polyvinylpyrrolidone; pH 5, 2-7.0; relative viscosity from 7, 0 to 15, 0.

Polyvinylpyrrolidone is used not only for the manufacture of plasma-replacing solutions (see Hemodez, Neohemodez), but also as a substitute for synovial fluid. For this, polyvinylpyrrolidone with a molecular weight of 35,000 + 5000 is used, which forms colloidal solutions with water.

A solution of polyvinylpyrrolidone (15%) is similar in physical properties to synovial fluid and is used as an artificial substitute for this fluid in diseases of the joints, accompanied by its absence or lack of joint space.

The introduction of the solution into the joint cavity improves the sliding of the articular surfaces, prevents the development of adhesions.

The drug is used for primary and secondary deforming arthrosis, mainly for lesions of the joints of the extremities with functional insufficiency without pronounced secondary synovitis.

The solution is administered intraarticularly in compliance with all asepsis rules 1 2 times a week. The solution remains in the cavity for 5 to 6 days.

The amount of solution depends on the volume of the joint. 4–6 ml are usually injected into the hip joint, 5–10 ml into the knee joint, 2–3 ml in the ulnar joint, and 1, 5–1.5 l into the interphalangeal joints.

The course of treatment consists of 4 to 6 injections. After 6 to 12 months, a second course is carried out.

The drug is well tolerated. However, there is evidence that in patients with a pronounced local process, increased synovitis symptoms and adverse changes in the composition of the synovial fluid are possible (see above).

Release form: in ampoules on 5 ml.

Storage: List B. At temperatures from - 20 to + 20 'C.